CD8A and neoplasm: Reportedly, chidamide selectively inhibits the activity of HDACs 1, 2, 3, and 10, demonstrating its anticancer functions as a genuine epigenetic modulator via the following mechanisms: induction of growth arrest and apoptosis in the blood and lymphoid-derived tumor cells; the reversal of epithelial-mesenchymal transitions and drug resistance in tumor cells; importantly, enhancement of natural killer (NK)-cell and antigen-specific CD8+ cytotoxic T-lymphocyte (CTL) mediated cellular antitumor immunity18–22.